GeoVax Labs (GOVX) Share-based Compensation (2010 - 2026)
GeoVax Labs (GOVX) posted quarterly Share-based Compensation of $1.3 million for Q2 2026, up 344.08% year-over-year from $292740.0 in Q2 2025, and up 415.62% quarter-over-quarter from $252124.0 in Q4 2025.
GeoVax Labs (GOVX) Share-based Compensation (2010 - 2026) Analysis & Trends
GeoVax Labs (GOVX) has reported Share-based Compensation for 17 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Share-based Compensation rose 344.08% year-over-year to $1.3 million; the TTM figure through Jun 2026 stood at $1.3 million (up 95.89% YoY), while the FY2025 annual figure was $1.4 million, up 159.44% from the prior year.
- Share-based Compensation climbed to $1.3 million in Q2 2026 per GOVX's latest filing, from $252124.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $2.2 million in Q1 2025 and bottomed at $101640.0 in Q2 2024.
- Historically, Share-based Compensation has averaged $391081.8 across 5 years, with a median of $227114.0 in 2023.
- Annual changes were most pronounced in 2024 — Share-based Compensation tumbled 55.03% — and 2025, when it soared 1294.74%.
- GeoVax Labs' Share-based Compensation stood at $251179.0 in 2022, then rose by 4.09% to $261458.0 in 2023, then plunged by 46.7% to $139345.0 in 2024, then jumped by 80.94% to $252124.0 in 2025, then soared by 415.62% to $1.3 million in 2026.
- Business Quant data shows GOVX's Share-based Compensation at $1.3 million in Q2 2026, $252124.0 in Q4 2025, and $277546.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | - |
| 10 | GeoVax Labs | 2.88 Mn | -262,319.87 | - | 1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Mn |
| Jun 30, 2026 | 1.30 Mn |
| Dec 31, 2025 | 252,124.00 |
| Dec 31, 2025 | 252,124.00 |
| Sep 30, 2025 | 277,546.00 |
| Sep 30, 2025 | 277,546.00 |
| Jun 30, 2025 | 292,740.00 |
| Jun 30, 2025 | 292,740.00 |
| Mar 31, 2025 | 2.20 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Dec 31, 2024 | 139,345.00 |
| Dec 31, 2024 | 139,345.00 |
| Sep 30, 2024 | 129,923.00 |
| Sep 30, 2024 | 129,923.00 |
| Jun 30, 2024 | 101,640.00 |
| Jun 30, 2024 | 101,640.00 |
| Mar 31, 2024 | 157,736.00 |
| Mar 31, 2024 | 157,736.00 |
| Dec 31, 2023 | 261,458.00 |
| Dec 31, 2023 | 261,458.00 |